The stock of Pfenex Inc (NYSEMKT:PFNX) is a huge mover today! The stock increased 5.68% or $0.54 on November 23, hitting $10.05. About 57,653 shares traded hands. Pfenex Inc (NYSEMKT:PFNX) has risen 11.67% since April 22, 2016 and is uptrending. It has outperformed by 6.26% the S&P500.
The move comes after 8 months positive chart setup for the $227.23 million company. It was reported on Nov, 24 by Barchart.com. We have $10.75 PT which if reached, will make NYSEMKT:PFNX worth $15.91 million more.
Analysts await Pfenex Inc (NYSEMKT:PFNX) to report earnings on March, 9. They expect $-0.68 EPS, down 83.78% or $0.31 from last year’s $-0.37 per share. After $1.46 actual EPS reported by Pfenex Inc for the previous quarter, Wall Street now forecasts -146.58% negative EPS growth.
According to Zacks Investment Research, “Pfenex Inc. is a clinical-stage biotechnology company developing and commercializing proteins. The company’s lead product candidate is PF582, a biosimilar candidate to Lucentis, for the potential treatment of patients with retinal diseases. It leverages its Pf?nex Expression Technology (TM) platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics. Pfenex Inc. is headquartered in San Diego, California.”
More important recent Pfenex Inc (NYSEMKT:PFNX) news were published by: Prnewswire.com which released: “Pfenex Inc. Announces Formation of Scientific Advisory Board” on October 19, 2016, also Prnewswire.com published article titled: “Pfenex Reports Second Quarter 2016 Results and Provides Business Update”, Prnewswire.com published: “Pfenex Reports Third Quarter 2016 Results and Provides Business Update” on November 09, 2016. More interesting news about Pfenex Inc (NYSEMKT:PFNX) was released by: Prnewswire.com and their article: “Pfenex To Report Third Quarter 2016 Results and Provide Business Update on …” with publication date: October 26, 2016.
PFNX Company Profile
Pfenex Inc., incorporated on November 19, 2009, is a clinical-stage biotechnology company. The Firm is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. The Company’s lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab). The Company’s next advanced product candidates are PF530 and PF708. PF530 is a biosimilar candidate to Betaseron (interferon beta-1b). PF708 is being developed as a therapeutically equivalent peptide to Forteo (teriparatide), which is for the treatment of osteoporosis. In addition to its three advanced product candidates, its pipeline includes over four other biosimilar candidates, as well as vaccines and next generation biologic candidates. The Company’s product candidates are enabled by its protein production platform, Pfenex Expression Technology.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.